Shares of Unilife Corp (NASDAQ:UNIS) ended Tuesday session in red amid volatile trading. The shares closed down -0.19 points or -7.12% at $2.48 with 92,896.00 shares getting traded. Post opening the session at $2.60, the shares hit an intraday low of $2.48 and an intraday high of $2.68 and the price vacillated in this range throughout the day. The company has a market cap of $42.70 million and the numbers of outstanding shares have been calculated to be 17.41 million shares.
Unilife Corporation is a medical device manufacturer and component supplier. The Company is engaged in the designing, development and manufacturing of injectable drug delivery systems. It has a portfolio of product platforms, including pre-filled syringes, wearable injectors, insulin delivery systems, disposable and reusable auto-injectors, drug reconstitution delivery systems, ocular delivery systems and other systems. The Company’s Pre-filled Syringes include Unifill platform that includes Unifill, Unifill Finesse, Unifill Select, Unifill Nexus and Unifill Allure. The Company offers ReadyToGo portfolio of wearable injectors. Its Imperium platform is designed to be prefilled with insulin and is supplied ready for multi-day wear. Its product configurations available within the EZMix platform include AutoMix Presto, EZMix Genesis, EZMix Engage and EZMix Prodigy. The Company’s Ocular delivery systems include Ocu-ject, Ocu-mix and Depot-ject.
Shares of Exelixis, Inc. (NASDAQ:EXEL) ended Tuesday session in red amid volatile trading. The shares closed down -0.09 points or -0.73% at $12.31 with 4.92 million shares getting traded. Post opening the session at $12.33, the shares hit an intraday low of $12.16 and an intraday high of $12.48 and the price vacillated in this range throughout the day. The company has a market cap of $2.93 billion and the numbers of outstanding shares have been calculated to be 230.33 million shares.
Exelixis, Inc. (EXEL) on August 31, 2016 announced that data from clinical trials of cabozantinib and cobimetinib will be the subject of 15 presentations at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, October 7 – 11, 2016.
Detailed results from CABOSUN, a randomized phase 2 clinical trial of cabozantinib compared with sunitinib in patients with previously untreated advanced renal cell carcinoma (RCC), will be presented at ESMO as a late-breaking abstract in the Genitourinary Tumours, Non-Prostate oral presentation session on Saturday, October 8. Additional poster presentations will detail the investigation of cabozantinib in other cancer settings, including in combination with nivolumab in metastatic urothelial carcinoma and other genitourinary cancers, as well as the evaluation of cobimetinib in combination studies across multiple tumor types.
“This year’s ESMO Congress provides Exelixis and our partners with the opportunity to present data across a broad spectrum of cancers and potential treatment combinations,” said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis. “We look forward to the first presentation of the CABOSUN data, which will provide more detail about the statistically significant and clinically meaningful improvement in progression-free survival for cabozantinib in patients with advanced renal cell carcinoma in the front-line setting. Our focus remains on further examining the potential of our therapies and moving these medicines through clinical development so they are available to patients and physicians as quickly as possible.”